Ketamine Pharmacology: A Clinical Review for Providers

Ketamine's pharmacology is genuinely unusual. A drug that was developed as a dissociative anesthetic in 1962, classified as a veterinary sedative in the 1970s, and largely ignored by psychiatry for four decades now produces antidepressant responses in treatment-resistant patients within hours, an effect that existing receptor models of depression could not have predicted. The mechanistic story that has emerged since Berman's landmark 2000 trial is still being written, but the outlines are now clear enough to inform clinical practice: ketamine does not work the way SSRIs work, and understanding the distinction is what allows a prescriber to dose intelligently, manage side effects rationally, and have credible conversations with patients about what the molecule is actually doing in their brains.

NMDA Receptor Antagonism

The NMDA receptor is the entry point to everything else ketamine does. Whether you're thinking about antidepressant effect, dissociative experience, cardiovascular response, or cognitive side effects, the trail leads back to how and where ketamine binds glutamate's primary ionotropic receptor. Understanding this node is the difference between prescribing ketamine by recipe and prescribing it with mechanistic fluency.

Primary Mechanism of Action

NMDA Receptor Function:

• Ketamine acts as a non-competitive NMDA receptor antagonist
• Preferential binding to extrasynaptic NR2B-containing receptors
• Voltage-dependent channel blocking mechanism
• Resultant glutamate system modulation and downstream effects

Dose-Response Relationships:

• Low-dose effects: Selective NMDA antagonism
• Moderate doses: Broader glutamate system modulation
• High doses: Additional receptor interactions (sigma, opioid, monoamine)

Neuroplasticity and Synaptic Effects

The receptor blockade is, paradoxically, upstream of what actually produces the antidepressant effect. The clinically meaningful cascade is downstream: a disinhibition of cortical glutamate release, an AMPA-receptor-mediated signaling surge, and the activation of protein synthesis machinery that rebuilds synapses the depressed brain had allowed to atrophy. Most of the mechanistic interest in ketamine over the last decade has concentrated here, because this is the step that distinguishes ketamine's antidepressant mechanism from every prior class of antidepressant.

Rapid Synaptic Changes:

• mTOR pathway activation within 30 minutes
• BDNF release and TrkB receptor activation
• Dendritic spine formation and synaptic strengthening
• Restoration of prefrontal cortex connectivity patterns

Clinical Pharmacokinetics

The pharmacokinetic profile is where the route-of-administration decision gets made, and each route produces a genuinely different clinical experience. An IV infusion and a sublingual troche are not interchangeable tools delivering the same drug at different speeds; they produce different peak plasma concentrations, different brain exposure curves, and correspondingly different subjective and therapeutic effects. A clinician who understands this picks a route for a reason, not because it's what the clinic is set up to do.

Route-Specific Considerations

Intravenous Administration:

• 100% bioavailability with immediate onset
• Peak plasma concentrations within 1-5 minutes
• Rapid distribution to brain tissue
• Suitable for acute treatment and clinic-based protocols

Sublingual Administration:

• 25-30% bioavailability with variable absorption
• Peak concentrations in 30-60 minutes
• Extended duration of action
• Appropriate for home-based treatment protocols

Metabolism and Elimination

The metabolic pathway matters more than most prescribers realize because norketamine, ketamine's principal metabolite, is itself pharmacologically active and may contribute meaningfully to the sustained portion of the antidepressant effect. This also explains why hepatic impairment is a relative contraindication that requires dose adjustment rather than a theoretical concern that can be safely ignored.

Hepatic Metabolism:

• Primary pathway: N-demethylation to norketamine
• Norketamine: Active metabolite with NMDA antagonist activity
• Hydroxylation and conjugation pathways
• Elimination half-life: 2.5-3 hours for parent compound

Clinical Efficacy Mechanisms

The question patients ask most often (how does this actually make me feel better?) does not have a short answer, because ketamine's antidepressant effect appears to operate through at least two temporally distinct mechanisms. The rapid onset effect, hours to days, is synaptic and reversible. The sustained effect, weeks to months, depends on structural changes that only consolidate if the neuroplastic window is actually used for therapeutic integration. Both tracks matter; neither alone explains the full clinical picture.

Antidepressant Effects

Rapid Onset Mechanisms:

• Immediate NMDA receptor blockade
• Glutamate surge and AMPA receptor activation
• mTOR-mediated protein synthesis
• Synaptic plasticity restoration within hours

Sustained Benefits:

• Structural synaptic changes
• Network connectivity improvements
• Stress response system normalization
• Neuroinflammation reduction

Anxiolytic Properties

Ketamine's effect on anxiety disorders, particularly generalized anxiety and PTSD, appears to operate through a parallel mechanism: dampening amygdala hyperactivity and facilitating fear extinction learning during the neuroplastic window. This is why combining ketamine with exposure-based psychotherapy during the 24-72 hours after a session produces outcomes that neither modality achieves on its own.

Anxiety Reduction Mechanisms:

• Amygdala hyperactivity suppression
• Fear extinction learning enhancement
• GABAergic system modulation
• HPA axis normalization

Clinical Dosing Considerations

Dose selection in ketamine therapy is an exercise in finding the therapeutic window rather than maximizing exposure. Pushing the dose higher does not produce a proportionally larger antidepressant effect; it produces a larger dissociative experience with diminishing marginal benefit on mood outcomes and increasing side-effect burden. The dosing ranges below reflect the band within which the clinical literature has consistently observed response.

Therapeutic Window Optimization

Depression Treatment:

• Optimal dosing: 0.5-1.0 mg/kg IV or equivalent sublingual
• Frequency: 2-3 times weekly initially, then maintenance
• Individual titration based on response and tolerance
• Monitoring for therapeutic vs. dissociative effects

Chronic Pain Applications:

• Lower doses often effective: 0.3-0.5 mg/kg
• Emphasis on anti-inflammatory and central sensitization effects
• Integration with multimodal pain management approaches
• Long-term tolerance considerations

Safety and Monitoring Implications

The safety profile of ketamine is remarkably benign at therapeutic doses, which is both the feature that makes the treatment viable and the feature that lulls undertrained programs into skipping monitoring that should not be skipped. The adverse events are uncommon but not vanishingly so, and each of them is predictable from the underlying pharmacology: the sympathomimetic cardiovascular response is the sigma-receptor interaction and the catecholamine release; the dissociation is the NMDA blockade doing what it does.

Cardiovascular Effects

Sympathomimetic Properties:

• Dose-dependent blood pressure and heart rate increases
• Peak effects 15-30 minutes post-administration
• Resolution typically within 2-4 hours
• Enhanced monitoring for patients with cardiovascular risk

Dissociative Effects Management

Dissociation is the aspect of ketamine that patients worry about most and that experienced clinicians worry about least. At therapeutic doses and in a properly prepared setting, mild to moderate dissociation is the expected experience, and in the treatment-resistant depression literature, there's suggestive evidence that it may correlate with better antidepressant response. Severe or distressing dissociation is a different clinical event and warrants dose reduction or route change rather than simply "pushing through."

Therapeutic vs. Problematic Dissociation:

• Mild dissociation may enhance therapeutic outcomes
• Severe dissociation increases adverse event risk
• Patient education about expected effects
• Environmental modifications to optimize experience

Conclusion

The pharmacology of ketamine is the strongest argument for treating it as a genuinely new class of psychiatric medicine rather than as a variation on existing antidepressants. A molecule that produces measurable antidepressant effect within hours through a receptor-level mechanism that existing drug development had entirely missed is a rare thing in psychiatry, and the clinical rigor it deserves matches that rarity. Prescribers who carry the mechanistic picture in their heads (who understand why the dose ranges are what they are, why the route matters, why the 72-hour integration window is biologically real) consistently produce better clinical outcomes than those who treat the drug as another SSRI with a weirder side-effect profile.

Frequently Asked Questions

How does ketamine work as an antidepressant?

Ketamine is a non-competitive NMDA-receptor antagonist. The simplified cascade: ketamine blocks NMDA receptors on inhibitory GABAergic interneurons, so these interneurons stop suppressing nearby glutamatergic neurons, producing a transient glutamate surge. That surge activates AMPA receptors, which activate the mTOR signaling pathway, which triggers release of BDNF (brain-derived neurotrophic factor), which drives growth of new dendritic spines and restores synaptic connectivity in mood-regulating brain regions (prefrontal cortex, hippocampus). The structural and functional changes happen within hours to days, not weeks.

Why does ketamine work so much faster than SSRIs?

Different mechanism, different timeline. SSRIs slowly increase synaptic serotonin, then rely on weeks of receptor adaptation, gene expression changes, and downstream neuroplasticity to produce clinical effect. Ketamine bypasses that adaptation; it directly triggers the neuroplasticity downstream of glutamate signaling. The result is rapid restoration of synaptic density and dendritic spine growth that SSRIs require weeks of indirect pathway activation to approximate. For patients whose depression involves glutamatergic dysregulation (often the case in TRD), this direct mechanism is what produces response when monoamine drugs haven't.

What's the difference between racemic ketamine and esketamine (Spravato)?

Ketamine exists in two enantiomeric forms: S-ketamine (esketamine) and R-ketamine (arketamine). Spravato is purified S-ketamine, FDA-approved for treatment-resistant depression as a nasal spray. Racemic ketamine is a 50/50 mix of both forms, the version used in most off-label psychiatric protocols including at-home sublingual treatment. S-ketamine has higher NMDA-receptor affinity and is more potent on a per-mg basis. R-ketamine has lower psychoactive effects and may have its own antidepressant mechanism. Clinical efficacy of racemic vs. esketamine is comparable in most studies, with active research on whether the R-form contributes meaningfully.

Does ketamine affect serotonin or dopamine systems?

Indirectly, yes, but it's not the primary mechanism. Ketamine has minimal direct activity at serotonin transporters or dopamine receptors at therapeutic psychiatric doses, which is why combining it with SSRIs rarely produces clinically significant serotonin syndrome. Indirect effects on monoamine systems likely occur downstream of the glutamate cascade, but they're secondary to the NMDA antagonism + AMPA activation + mTOR/BDNF cascade that drives the antidepressant response. The clinical implication: ketamine produces antidepressant effects through a mechanism mostly orthogonal to SSRIs, which is why patients who fail SSRIs often respond to ketamine.

Refer a patient or get a curbside

If you have a patient who'd be a fit for ketamine and want to discuss a specific case before referring, the phone line is faster than email. For routine patient referrals, the eligibility screen below is the simplest path; we'll handle the rest and send you back a summary.

• Patient eligibility screen: tovanihealth.com/eligibility (5 minutes, FL and NJ residents)
• Provider line: 561-468-6981 (curbside questions about a specific case welcome)
• What you get back: an evaluation summary with the treatment plan and any questions for your team after the consultation.

Benjamin Soffer, DO — Tovani Health

Related professional reading: SSRI vs ketamine pharmacological comparison, evidence-based outcomes review, clinical protocols and patient selection, psychiatric consultation protocols.